Login to Your Account

Clinic Roundup

Thursday, February 21, 2013

• Onyx Pharmaceuticals Inc., of South San Francisco, said Leukemia published results from the Phase II study known as PX-171-005, testing Kyprolis (carfilzomib) in patients with relapsed and refractory multiple myeloma and varying degrees of renal insufficiency.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription